Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities, as per the MHRA authorisation
Does BCBSNC cover Wegovy for weight loss
Instead of pushing every patient to the maximum dose, clinicians may maintain individuals at lower doses that still produce meaningful metabolic effects
| Substance | Receptor profile | Trial | Weight change | Placebo | | --- | --- | --- | --- | --- | | Retatrutide | GIP/GLP-1/glucagon | Phase 2 (48 wk) | -8.7 to -24.2 % | -2.1 % | | Tirzepatide | GIP/GLP-1 | SURMOUNT-1 (72 wk) | -16.0 to -22.5 % | -3.1 % | | Semaglutide | GLP-1 | STEP 1 (68 wk) | -14.9 % | -2.4 % | | Cagrilintide + semaglutide | Amylin + GLP-1 | Phase 1b (20 wk) | -15.7 to -17.1 % | -9.8 %* | | CagriSema | Amylin + GLP-1 | REDEFINE 1 (68 wk) | -20.4 % | -3.0 % | *Comparator arm semaglutide alone
Together, these effects support gradual, consistent weight loss over time
PT-141: how it works and what to expect PT-141 is also known as bremelanotide